BARD OBTAINS BALLOON-EXPANDABLE CORONARY STENT THROUGH ACQUISITION OF CONTROLLING STAKE IN X-TRODE; FIRM PLANNING PROSTATE CANCER TEST LAUNCHES
This article was originally published in The Gray Sheet
Executive SummaryBard is gaining its second coronary stent franchise through the purchase of a majority stake in X-Trode, a Bologna, Italy-based company developing a balloon-expandable stainless steel stent.
You may also be interested in...ï»¿
The North American trade organization’s new website offers consumers a gateway into the world of fragrance. Providing a “deep dive” into 50 fragrance ingredients, as well as overviews of perfumery, key regulations, and industry safety practices and sustainability efforts, the site extends FCA’s work to engage and inform consumers at a time of growing interest in manufactured scents.
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.